Shuttle Pharmaceuticals Holdings (SHPH) Research & Development (2021 - 2026)

Shuttle Pharmaceuticals Holdings has reported Research & Development for 6 years, with the latest figure at $267240.0 in Q1 2026.

• On a quarterly basis, Research & Development fell 83.02% year-over-year to $267240.0 in Q1 2026; TTM through Mar 2026 was $2.7 million, a 40.34% decrease from a year earlier, with the FY2025 full-year figure at $4.1 million, up 12.05% from the prior year.
• Research & Development was $267240.0 for Q1 2026 at Shuttle Pharmaceuticals Holdings, down from $511878.0 in the prior quarter.
• The five-year high for Research & Development was $1.6 million in Q1 2025, with the low at -$1436.0 in Q4 2022.
• Average Research & Development over 5 years is $736425.9, with a median of $710449.0 recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Research & Development slumped 100.32% in 2022, then jumped 49574.16% in 2023.
• Over 5 years, Research & Development stood at -$1436.0 in 2022, then surged by 49574.16% to $710449.0 in 2023, then soared by 38.84% to $986409.0 in 2024, then slumped by 48.11% to $511878.0 in 2025, then sank by 47.79% to $267240.0 in 2026.
• The last three Research & Development figures came in at $267240.0 (Q1 2026), $511878.0 (Q4 2025), and $943478.0 (Q3 2025), per Business Quant data.